Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) saw unusually-high trading volume on Tuesday . Approximately 4,448,734 shares were traded during mid-day trading, an increase of 834% from the previous session’s volume of 476,474 shares.The stock last traded at $0.70 and had previously closed at $0.65.
Several institutional investors and hedge funds have recently added to or reduced their stakes in EBIO. Spark Investment Management LLC bought a new position in shares of Eleven Biotherapeutics during the second quarter valued at about $148,000. Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the second quarter worth about $175,000. Vanguard Group Inc. raised its position in Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 30,600 shares during the period. Finally, Municipal Employees Retirement System of Michigan bought a new stake in Eleven Biotherapeutics in the third quarter worth about $382,000. 4.19% of the stock is currently owned by institutional investors.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.